Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
Public ClinicalTrials.gov record NCT03532009. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicentre, Three Month Duration Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
Study identification
- NCT ID
- NCT03532009
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 182 participants
Conditions and interventions
Conditions
Interventions
- Sodium Zirconium Cyclosilicate Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 150 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 25, 2018
- Primary completion
- May 21, 2020
- Completion
- May 21, 2020
- Last update posted
- Jun 14, 2021
2018 – 2020
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | National City | California | 91950 | — |
| Research Site | Stanford | California | 94305 | — |
| Research Site | Waterbury | Connecticut | 06708 | — |
| Research Site | Miami | Florida | 33133 | — |
| Research Site | New Smyrna Beach | Florida | 32169 | — |
| Research Site | Port Charlotte | Florida | 33952 | — |
| Research Site | Indianapolis | Indiana | 46260 | — |
| Research Site | Alexandria | Louisiana | 71301 | — |
| Research Site | Boston | Massachusetts | 02115 | — |
| Research Site | Flint | Michigan | 48504 | — |
| Research Site | Brooklyn | New York | 11204 | — |
| Research Site | Wyomissing | Pennsylvania | 19610 | — |
| Research Site | Rapid City | South Dakota | 57701 | — |
| Research Site | El Paso | Texas | 79935 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03532009, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 14, 2021 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03532009 live on ClinicalTrials.gov.